BioInvent: Option and License Deal with Exelixis
Research Note
2022-06-16
10:00
Redeye views the deal with Exelixis, which provides BioInvent with a USD 25m upfront fee, as a useful cash injection and another validation of its core platform technologies.
RR
Richard Ramanius
Disclosures and disclaimers